Alteogen Creating a New Future
Alteogen is a leading bio venture company whose portfolio includes next-generation bio-better, with improved efficacy in comparison with existing biologics, and biosimilars that demonstrate “comparability” to the approved biologics with proprietary platform technology.
- NexP™ Fusion Technology – Next generation persistent technology which utilizes human A1AT (ALPHA-1 Anti-trypsin) protein, abundant in human blood, as the protein carrier which increases half-life of biomedicines
NexMab™ ADC Technology – Proprietary Antibody-Drug Conjugate (ADC) technology with superior stability, efficacy, and economical feasibility
Hybrozyme™ Technology – Novel human hyaluronidase PH20 variant for subcutaneous (SC) drug delivery conversion from IV injection with improved thermal stability
- Biosimilars – Differentiated biosimilars with proprietary technology
Alteogen is preparing better future by focusing on the three cutting edge areas, Hybrozyme™, Long-acting bio-better, proprietary antibody-drug conjugate (ADC), and monoclonal antibody biosimilars.
